FAMVIR 500 MG
FAMCICLOVIR : 500 MG · DIN 02177102 · SEARCHLIGHT PHARMA INC
Health Canada status: MARKETED
What is FAMVIR?
FAMVIR 500 MG contains FAMCICLOVIR : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02177102, held by SEARCHLIGHT PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 13-Feb-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FAMVIR used for?
FAMVIR (famciclovir) tablets are indicated for the treatment of acute herpes zoster (shingles), for the treatment or suppression of recurrent episodes of genital herpes in immunocompetent adults, and for the treatment of recurrent episodes of mucocutaneous herpes simplex infections in HIV - infected patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is FAMVIR called?
The same molecule, FAMCICLOVIR, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| APO-Famciclovir | Latin | Australia |
| FAMCICLOVIR-WGR | Latin | Australia |
| Ezovir | Latin | Australia |
| Zostivr | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02177102 |
|---|---|
| Brand name | FAMVIR |
| Generic / active ingredient | FAMCICLOVIR : 500 MG |
| Manufacturer | SEARCHLIGHT PHARMA INC |
| Strength | 500 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AB09 FAMCICLOVIR |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 13-Feb-2025 |
| Original market date | 1995-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02177102 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2177102 |
| Brand name | FAMVIR |
| Active ingredient / INN | FAMCICLOVIR : 500 MG |
| ATC code | J05AB09 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J05 |
| AHFS class | 28:08.04.92 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | SEARCHLIGHT PHARMA INC |
How is it stored and handled?
Store at controlled room temperature (15 - 25 °C).
How is it supplied?
125 mg in blister packages of 10. 250 mg in bottles of 30 or 60 and in blister packages of 30. 500 mg in bottles of 30 or 60 and in blister packages of 21.
Which pack is which?
| Strength on the label | 500 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | 125 mg in blister packages of 10. 250 mg in bottles of 30 or 60 and in blister packages of 30. 500 mg in bottles of 30 or 60 and in blister packages of 21. |
| Storage | Store at controlled room temperature (15 - 25 °C). |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code J05AB09 FAMCICLOVIR. 6 of 36 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-FAMCICLOVIR | 125 MG | TABLET | APOTEX INC | MARKETED | DIN 02292025 |
| APO-FAMCICLOVIR | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 02292041 |
| APO-FAMCICLOVIR | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02292068 |
| FAMVIR | 125 MG | TABLET | SEARCHLIGHT PHARMA INC | MARKETED | DIN 02229110 |
| FAMVIR | 250 MG | TABLET | SEARCHLIGHT PHARMA INC | MARKETED | DIN 02229129 |
| ACT FAMCICLOVIR | 125 MG | TABLET | TEVA CANADA LIMITED | DORMANT | DIN 02305682 |
| ACT FAMCICLOVIR | 250 MG | TABLET | TEVA CANADA LIMITED | DORMANT | DIN 02305690 |
| ACT FAMCICLOVIR | 500 MG | TABLET | TEVA CANADA LIMITED | DORMANT | DIN 02305704 |
| AURO-FAMCICLOVIR | 125 MG | TABLET | AURO PHARMA INC | APPROVED | DIN 02431564 |
| AURO-FAMCICLOVIR | 250 MG | TABLET | AURO PHARMA INC | APPROVED | DIN 02431572 |
Who else supplies FAMCICLOVIR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FAMCICLOVIR appears in 157 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does FAMCICLOVIR cost around the world?
FAMCICLOVIR is listed on 10 national price registers Nexara tracks, across 90 pack listings published on 9 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Australia | ex-manufacturer | 7 | 26 | 08 Sep 2026 |
| United States | acquisition | 3 | 18 | 03 Sep 2026 |
| Italy | prezzo al pubblico (classe A) | 8 | 12 | 02 Sep 2026 |
| Spain | PVP con IVA (public price) | 9 | 9 | 05 Sep 2026 |
| Greece | producer price (ex-factory) | 6 | 6 | 03 Sep 2026 |
| South Africa | single exit price | 5 | 6 | 01 Sep 2026 |
| Saudi Arabia | public | 3 | 4 | 01 Sep 2026 |
| United Arab Emirates | public | 3 | 3 | 31 Aug 2026 |
| Bahrain | retail (max) | 1 | 3 | 01 Sep 2026 |
| United Kingdom | hospital | 3 | 3 | 31 Aug 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.